Fortress Biotech, Inc. (FBIO)
2.04
-0.01
(-0.49%)
USD |
NASDAQ |
Oct 07, 16:00
2.06
+0.02
(+0.98%)
After-Hours: 20:00
Fortress Biotech Profit Margin (Quarterly) : 3.22% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.22% |
| March 31, 2026 | |
| December 31, 2025 | -33.57% |
| September 30, 2025 | 50.07% |
| June 30, 2025 | -71.00% |
| March 31, 2025 | -187.9% |
| December 31, 2024 | -174.0% |
| September 30, 2024 | -182.5% |
| June 30, 2024 | -193.5% |
| March 31, 2024 | -299.5% |
| December 31, 2023 | -145.3% |
| September 30, 2023 | -30.86% |
| June 30, 2023 | -341.1% |
| March 31, 2023 | -443.7% |
| December 31, 2022 | -350.2% |
| September 30, 2022 | -321.0% |
| June 30, 2022 | -285.6% |
| March 31, 2022 | -206.8% |
| December 31, 2021 | -374.9% |
| September 30, 2021 | -217.5% |
| June 30, 2021 | -136.7% |
| March 31, 2021 | -225.0% |
| December 31, 2020 | -149.0% |
| Date | Value |
|---|---|
| September 30, 2020 | -316.2% |
| June 30, 2020 | -301.0% |
| March 31, 2020 | -186.3% |
| December 31, 2019 | -296.1% |
| September 30, 2019 | -255.5% |
| June 30, 2019 | -297.1% |
| March 31, 2019 | -251.0% |
| September 30, 2018 | -603.7% |
| June 30, 2018 | -422.5% |
| March 31, 2018 | -612.3% |
| December 31, 2017 | -57.41% |
| September 30, 2017 | -77.44% |
| June 30, 2017 | -45.27% |
| March 31, 2017 | -32.59% |
| December 31, 2016 | -168.9% |
| September 30, 2016 | -1.74K% |
| June 30, 2016 | -734.9% |
| March 31, 2016 | -2.52K% |
| December 31, 2015 | -4.46K% |
| September 30, 2015 | -79.42K% |
| June 30, 2015 | |
| March 31, 2015 | -2.51K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | -- |
| Kura Oncology, Inc. | -327.3% |
| Spero Therapeutics, Inc. | -- |
| ACADIA Pharmaceuticals, Inc. | 10.23% |
| Alnylam Pharmaceuticals, Inc. | 12.74% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | 123.2% |
| Return on Assets | 58.81% |
| Return on Invested Capital | 79.78% |
| Gross Profit Margin (Quarterly) | 61.50% |
| Operating Margin (Quarterly) | -53.46% |
| Return on Net Operating Assets | 182.0% |